Telomir reports in vitro data: Telomir-1 inhibits UTX and modestly targets Tankyrases

Telomir Pharmaceuticals, Inc.

Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase linked to cancer, aging, neurodegeneration.
Low-level inhibition of Tankyrases (PARP5A/B) may disrupt Wnt/β-catenin pathway without telomere shortening risks.
Selectivity vs GCN5L2 suggests cleaner safety margin vs other epigenetic drugs.
Prior in vivo data showed reactivation of tumor suppressors STAT1/TMS1 and telomere elongation.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.